HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mease, P J Articles by Antoni, C E Search for Related Content PubMed PubMed Citation Articles by Mease, P J Articles by Antoni, C E

Psoriatic arthritis treatment: biological response modifiers

¹ Seattle Rheumatology Associates, Swedish Medical Center Rheumatology Research Division, Clinical Professor, University of Washington School of Medicine, Seattle, WA, USA
² Department of Medicine III, Friedrich-Alexander University Erlangen-Nuernberg, Germany

Correspondence to:
Correspondence to:
Dr P J Mease
Seattle Rheumatology Associates, 1101 Madison St, 10th floor, Seattle, WA 98104, USA; pmease{at}nwlink.com

In recent years there has been a surge of interest in the treatment of chronic inflammatory disorders as a result of the development and application of targeted biological therapies. The elucidation of the overlapping cellular and cytokine immunopathology of such diverse conditions as rheumatoid arthritis (RA), Crohn’s disease, and psoriasis points to specific targets for bioengineered proteins or small molecules.

Similar to clinical trials in RA, trials in psoriatic arthritis (PsA) have shown excellent clinical results with the tumour necrosis factor (TNF) blockers, etanercept, infliximab, and adalimumab in a variety of domains including the joints, quality of life, function, and slowing of disease progress as evidenced radiologically. In addition, these agents have shown benefit in domains more unique to PsA, such as the skin lesions of psoriasis, enthesitis, and dactylitis, pointing out the similar pathogenesis of the disease in the skin, the tendons, and the synovial membrane. This therapy has been generally safe and well tolerated in clinical trials of PsA.

Other logical candidates for targeted therapy in development include other anti-TNF agents, costimulatory blockade agents that affect T cell function, blockers of other cytokines such as interleukin (IL)-1, 6, 12, 15, or 18, and B cell modulatory medicines. Also, it will be useful to learn more about the effects of combining traditional disease modifying drugs and the newer biologicals.

Abbreviations: ACR, American College of Rheumatology; DMARD, disease modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; MTX, methotrexate; PsA, psoriatic arthritis; PsARC, PsA response criteria; PASI, Psoriasis Area and Severity Index; RA, rheumatoid arthritis; TNF, tumour necrosis factor

Keywords: psoriatic arthritis; anti-TNF; biologic therapy; psoriasis

This article has been cited by other articles:

				F. Cantini, L. Niccoli, C. Nannini, E. Cassara, P. Pasquetti, I. Olivieri, and C. Salvarani Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs Rheumatology, June 1, 2008; 47(6): 872 - 876. [Abstract] [Full Text] [PDF]

				L E Kristensen, A Gulfe, T Saxne, and P Geborek Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register Ann Rheum Dis, March 1, 2008; 67(3): 364 - 369. [Abstract] [Full Text] [PDF]

				P. Szodoray, P. Alex, C. M. Chappell-Woodward, T. M. Madland, N. Knowlton, I. Dozmorov, M. Zeher, J. N. Jarvis, B. Nakken, J. G. Brun, et al. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system Rheumatology, March 1, 2007; 46(3): 417 - 425. [Abstract] [Full Text] [PDF]

				A. Kavanaugh Pharmacoeconomic considerations in the treatment of psoriatic arthritis Rheumatology, July 1, 2006; 45(7): 790 - 791. [Full Text] [PDF]

				New drugs for peripheral joint psoriatic arthritis DTB, January 1, 2006; 44(1): 1 - 5. [Abstract] [Full Text] [PDF]

				P J Mease, C E Antoni, D D Gladman, and W J Taylor Psoriatic arthritis assessment tools in clinical trials Ann Rheum Dis, March 1, 2005; 64(suppl_2): ii49 - ii54. [Abstract] [Full Text] [PDF]

				P A Ory, D D Gladman, and P J Mease Psoriatic arthritis and imaging Ann Rheum Dis, March 1, 2005; 64(suppl_2): ii55 - ii57. [Abstract] [Full Text] [PDF]

				P Nash and D O Clegg Psoriatic arthritis therapy: NSAIDs and traditional DMARDs Ann Rheum Dis, March 1, 2005; 64(suppl_2): ii74 - ii77. [Abstract] [Full Text] [PDF]